Latest Breaking News On - Peng liang - Page 1 : vimarsana.com
14.06.2022 - - Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and efficacy of SCB-219M in cancer patients with chemotherapy-induced thrombocytopenia, a serious treatment-associated platelet count disorder - - Interim safety and recommended ... Seite 1
ChinaPeng-liangClover-biopharmaceuticals-ltdChief-scientific-officer